TG Therapeutics Q1 2026 Earnings Preview
Source: SeekingAlpha
2026-05-05 12:01:26 ET
More on TG Therapeutics
- TG Therapeutics: Flawless Execution And $500 Million Non-Dilutive Capital Bolster Outlook
- TG Therapeutics: Briumvi Performance Aiding Upside, Buybacks Limiting Downside
- TG Therapeutics: 'Strong Buy' On BRIUMVI's Massive Growth And Possible Expansion
- TG Therapeutics secures $750M credit facility with Blue Owl, boosts buyback to $300M
- TG Therapeutics outlines $825M–$850M BRIUMVI 2026 guidance while accelerating subcutaneous program
Read the full article on Seeking Alpha
For further details see:
TG Therapeutics Q1 2026 Earnings Preview
TG Therapeutics Inc.
NASDAQ: TGTX
TGTX Trading
2.13% G/L:
$41.39 Last:
1,092,407 Volume:
$40.58 Open:
TGTX Latest News
June 03, 2026 07:30:00 am
TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)
June 02, 2026 07:30:00 am
TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference
June 01, 2026 07:30:00 am
TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology
May 28, 2026 07:30:00 am
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference
TGTX Stock Data
$4,661,971,279
141,867,445
0.11%
146
N/A
Biotechnology & Life Sciences
Healthcare
US
Morrisville
